Three specifications of irbesartan hydrochlorothiazide tablets of Huahai Pharmaceutical Co., Ltd. have been approved by FDA for listing

In the evening of May 12, Huahai pharmaceutical announced that the company's three specifications of irbesartan hydrochlorothiazide tablets were approved by FDA for listing Irbesartan hydrochlorothiazide, which is used to treat essential hypertension, is expected to be available in the United States in June According to the public information, the original manufacturer of irbesartan hydrochlorothiazide tablets is Sanofi, and there are more than 10 generic pharmaceutical enterprises including Huahai pharmaceutical Industry insiders pointed out that the price of generic drugs in the United States is completely market-oriented, and the competition pattern of irbesartan hydrochlorothiazide tablets is fierce It is worth mentioning that according to the time sequence of Huahai's application for generic drugs in the United States, there are also two products of bupropion hydrochloride sustained-release tablets and levetiracetam sustained-release tablets which are also expected to be approved in the near future Among them, bupropion hydrochloride sustained-release tablets are mainly for depression, and levetiracetam sustained-release tablets are antiepileptic drugs Huahai pharmaceutical industry is transforming from API to preparation business Because the company's preparation products are mainly generic drugs with "running volume", the sales scale depends on the number of preparation varieties to a large extent The company has obtained 13 FDA preparation numbers through independent research and development and purchase According to Shenyin Wanguo Research Report, in 2013, the company realized a revenue of 300 million yuan from its own export preparations, accounting for 13% of the company's revenue.